Mike Gladstone, global president and general manager of Pfizer Inflammation and Immunology unit, said that the acquisition of Arena is in line with the company’s capabilities and expertise in immunology and inflammatory-related conditions. Over the years, Pfizer has successfully created an innovation engine that develops potential medicines for patients worldwide with chronic and debilitating immuno-inflammatory conditions. The company understands that there is an urgent need to look into other treatment options with high potential, which is where Arena’s cannabinoid-drug pipeline comes in.
Slapwoods is announcing its first-ever official collaboration with DJ Screw, the late Houston legend whose…
It could be so easy to believe that cannabis culture is something that has been…
Modern cultivation techniques and spiritual practices collide with Pink Boost Goddess on our next Legendary…
Animal rescuers and advocacy groups say dogs living on Skid Row are suffering from neglect,…
This article originally appeared in High Times’ 50th Anniversary print issue. It is an excerpt…
How Montana built a legal cannabis market from a thin medical marijuana law, federal raids,…